{"id":"folotyn","rwe":[],"tags":[],"phase":"discontinued","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":["Anemia","Bone marrow depression","Breastfeeding (mother)","Impaired renal function disorder","Liver function tests abnormal","Neutropenic disorder","Pregnancy, function","Stomatitis","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"discontinued","trials":["NCT01188876","NCT01118624","NCT03719105","NCT06671717","NCT00024245","NCT07225985","NCT00004238","NCT02013362","NCT03349333","NCT01206465","NCT04747236","NCT02106650","NCT00606502","NCT00554827","NCT01114282","NCT01134341","NCT01532011","NCT00052442","NCT01482962","NCT01178944","NCT03598998","NCT03355768","NCT01420679","NCT00364923","NCT00998946","NCT02594267","NCT02551718","NCT03150602","NCT06072131","NCT01183065","NCT01129206","NCT01336933","NCT00481871","NCT03356678","NCT01626664","NCT07036133","NCT03161223","NCT00722553","NCT01820091","NCT07234162","NCT01947140","NCT06561048","NCT03240211","NCT01789723"],"aliases":["Folotyn - (Pralatrexate)","Pralatrexate"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"aiSummary":"","brandName":"Folotyn","companyId":"acrotech-biopharma-inc","ecosystem":[],"mechanism":{"target":"Folate transporter 1, Proton-coupled folate transporter, Dihydrofolate reductase","novelty":"","modality":"Small molecule","drugClass":"","explanation":"","oneSentence":"","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Acrotech Biopharma Inc.","competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"Folotyn","indications":{"approved":[{"name":"Peripheral T-cell lymphoma","diseaseId":"peripheral-t-cell-lymphoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01188876","phase":"Phase 1","title":"Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"Massachusetts General Hospital","isPivotal":false,"enrollment":50,"indication":"Ovarian Cancer, Fallopian Tube Cancer","completionDate":"2017-07"},{"nctId":"NCT01118624","phase":"Phase 2","title":"Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":22,"indication":"Breast Cancer, Breast Tumors","completionDate":"2012-07"},{"nctId":"NCT03719105","phase":"EARLY/Phase 1","title":"Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lym","status":"RECRUITING","sponsor":"New York Medical College","isPivotal":false,"enrollment":40,"indication":"NK-Cell Lymphoma, NK-Cell Leukemia","completionDate":"2028-12-31"},{"nctId":"NCT06671717","phase":"NA","title":"Pralatrexate Combined With Chidamide Bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","isPivotal":false,"enrollment":25,"indication":"Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma","completionDate":"2027-07"},{"nctId":"NCT00024245","phase":"Phase 1","title":"Phase I and Clinical Pharamcologic Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Combination With Probenecid in Adults With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":0,"indication":"Unspecified Adult Solid Tumor, Protocol Specific","completionDate":"2003-04"},{"nctId":"NCT07225985","phase":"Phase 1","title":"Pralatrexate and Bendamustine With 3 Gy TBI as a New Reduced Intensity Conditioning (RIC) Regimen for Allogeneic HCT for T-Cell Lymphoma Patients Who Are in Untreated R/R, or in Remission With MRD","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","isPivotal":false,"enrollment":50,"indication":"Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma","completionDate":"2030-11-15"},{"nctId":"NCT00004238","phase":"Phase 2","title":"A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Patients With Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":0,"indication":"Lung Cancer","completionDate":"2002-06"},{"nctId":"NCT02013362","phase":"Phase 1","title":"Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Mundipharma K.K.","isPivotal":false,"enrollment":25,"indication":"Peripheral T-cell Lymphoma","completionDate":"2017-09"},{"nctId":"NCT03349333","phase":"Phase 3","title":"A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Mundipharma (China) Pharmaceutical Co. Ltd","isPivotal":true,"enrollment":85,"indication":"Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma","completionDate":"2018-05-21"},{"nctId":"NCT01206465","phase":"Phase 1","title":"A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-hour Infusion of 5- Fluorouracil Given Every Other Week in Adult Patients With Solid Tumors","status":"COMPLETED","sponsor":"University of Nebraska","isPivotal":false,"enrollment":29,"indication":"Unspecified Adult Solid Tumor, Protocol Specific","completionDate":"2017-06-01"},{"nctId":"NCT04747236","phase":"Phase 2","title":"A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients With Relapse or Refractory Peripheral T-cell Lymphoma (PTCL)","status":"RECRUITING","sponsor":"University of Virginia","isPivotal":false,"enrollment":50,"indication":"PTCL","completionDate":"2030-06-02"},{"nctId":"NCT02106650","phase":"Phase 2","title":"A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancie","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":36,"indication":"Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma","completionDate":"2019-06"},{"nctId":"NCT00606502","phase":"Phase 2","title":"A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","isPivotal":false,"enrollment":201,"indication":"Non-small Cell Lung Cancer","completionDate":"2010-06-24"},{"nctId":"NCT00554827","phase":"Phase 1","title":"A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":55,"indication":"Cutaneous T-cell Lymphoma","completionDate":"2012-02"},{"nctId":"NCT01114282","phase":"Phase 1","title":"A Phase I Study of Bortezomib (VELCADE) in Combination With Pralatrexate in Relapsed/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Stanford University","isPivotal":false,"enrollment":11,"indication":"Multiple Myeloma","completionDate":""},{"nctId":"NCT01134341","phase":"Phase 1","title":"A Phase 1, Open-label, Dose-finding Study of Pralatrexate Plus Systemic Bexarotene in Patients With Relapsed or Refractory Cutaneous T Cell Lymphoma","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":34,"indication":"Cutaneous T-cell Lymphoma, Mycosis Fungoides","completionDate":"2015-08"},{"nctId":"NCT01532011","phase":"Phase 1","title":"A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","isPivotal":false,"enrollment":72,"indication":"Advanced Cancers, Solid Tumors","completionDate":"2016-06"},{"nctId":"NCT00052442","phase":"Phase 1","title":"A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphomas and Hodgkin's Disease","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","isPivotal":false,"enrollment":72,"indication":"Lymphoma","completionDate":"2009-03"},{"nctId":"NCT01482962","phase":"Phase 3","title":"A Phase 3, Randomized, Two-Arm, Open-Label, Multicenter, International Trial of Alisertib (MLN8237) or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral ","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","isPivotal":true,"enrollment":271,"indication":"Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma","completionDate":"2017-12-18"},{"nctId":"NCT01178944","phase":"Phase 2","title":"Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","isPivotal":false,"enrollment":35,"indication":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Undifferentiated Carcinoma","completionDate":"2015-11"},{"nctId":"NCT03598998","phase":"Phase 1","title":"A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","isPivotal":false,"enrollment":13,"indication":"Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype","completionDate":"2026-02-26"},{"nctId":"NCT03355768","phase":"Phase 3","title":"Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)","status":"WITHDRAWN","sponsor":"Jennifer Amengual","isPivotal":true,"enrollment":0,"indication":"Lymphoma, T-Cell, Peripheral","completionDate":"2018-11-01"},{"nctId":"NCT01420679","phase":"Phase 3","title":"A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients Previously Undiagnosed Peripheral T-cell Lymphoma Who Achieved an Objective Response After Initial T","status":"TERMINATED","sponsor":"Spectrum Pharmaceuticals, Inc","isPivotal":true,"enrollment":21,"indication":"Peripheral T-cell Lymphoma","completionDate":"2017-12"},{"nctId":"NCT00364923","phase":"Phase 2","title":"A Multi-Center, Phase 2, Open-Label Study of (RS)-10-Propargyl-10-Deazaaminopterin (Pralatrexate) With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Peripheral T-c","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":115,"indication":"Peripheral T-cell Lymphoma","completionDate":"2009-02-24"},{"nctId":"NCT00998946","phase":"Phase 2","title":"A Phase 2, Single-arm, Open-label, Multi-center Study of Pralatrexate in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Spectrum Pharmaceuticals, Inc","isPivotal":false,"enrollment":29,"indication":"Lymphoma, B-Cell","completionDate":"2012-08"},{"nctId":"NCT02594267","phase":"Phase 1","title":"A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":48,"indication":"Peripheral T-Cell Lymphoma (PTCL)","completionDate":"2020-10-08"},{"nctId":"NCT02551718","phase":"NA","title":"Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data","status":"COMPLETED","sponsor":"University of Washington","isPivotal":false,"enrollment":34,"indication":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia","completionDate":"2021-05-13"},{"nctId":"NCT03150602","phase":"Phase 4","title":"A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy","status":"UNKNOWN","sponsor":"Taiwan Mundipharma Pharmaceuticals Ltd.","isPivotal":false,"enrollment":22,"indication":"Peripheral T Cell Lymphoma, Progression, Disease","completionDate":"2020-12-31"},{"nctId":"NCT06072131","phase":"Phase 3","title":"A Phase 3, Randomized, Open-Label Study Comparing the Efficacy and Safety of the Combination of Beleodaq-CHOP or Folotyn-COP to the CHOP Regimen Alone in Newly Diagnosed Patients With Peripheral T-Cel","status":"RECRUITING","sponsor":"Acrotech Biopharma Inc.","isPivotal":true,"enrollment":504,"indication":"Peripheral T Cell Lymphoma","completionDate":"2030-11"},{"nctId":"NCT01183065","phase":"Phase 2","title":"A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","isPivotal":false,"enrollment":13,"indication":"Head and Neck Cancer","completionDate":"2014-04"},{"nctId":"NCT01129206","phase":"Phase 2","title":"Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy.","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","isPivotal":false,"enrollment":6,"indication":"Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction","completionDate":""},{"nctId":"NCT01336933","phase":"Phase 2","title":"A Phase II Study of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-","status":"COMPLETED","sponsor":"University of Nebraska","isPivotal":false,"enrollment":34,"indication":"Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma","completionDate":"2016-12-28"},{"nctId":"NCT00481871","phase":"Phase 1","title":"A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":119,"indication":"Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma","completionDate":"2011-08"},{"nctId":"NCT03356678","phase":"N/A","title":"Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma: a Multicenter, Multinational Retrospective Analysis","status":"COMPLETED","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":33,"indication":"Relapsed or Refractory Peripheral T-cell Lymphoma","completionDate":"2017-06-30"},{"nctId":"NCT01626664","phase":"Phase 2","title":"Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)","status":"COMPLETED","sponsor":"Kyowa Kirin, Inc.","isPivotal":false,"enrollment":71,"indication":"Adult T-cell Leukemia-Lymphoma","completionDate":"2018-02"},{"nctId":"NCT07036133","phase":"Phase 1","title":"A Phase 1, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Functio","status":"RECRUITING","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":24,"indication":"Advanced Solid Tumors, Hematologic Malignancies","completionDate":"2027-09"},{"nctId":"NCT03161223","phase":"Phase 1","title":"Phase 1/2a Study of Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Aza and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine for Treatment of Patie","status":"RECRUITING","sponsor":"University of Virginia","isPivotal":false,"enrollment":148,"indication":"Lymphoma, T-Cell","completionDate":"2023-02"},{"nctId":"NCT00722553","phase":"Phase 2","title":"A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder","status":"COMPLETED","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":30,"indication":"Carcinoma, Transitional Cell, Bladder Cancer","completionDate":"2011-09"},{"nctId":"NCT01820091","phase":"Phase 1","title":"An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Recei","status":"WITHDRAWN","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":0,"indication":"Non-Small Cell Lung Cancer","completionDate":"2015-04"},{"nctId":"NCT07234162","phase":"Phase 3","title":"A Phase 3, Open-Label, Randomized, Multinational Study to Investigate the Anti-tumor Efficacy of Golidocitinib Versus Investigator's Choice in Adult Patients With Relapsed/Refractory Peripheral T-cell","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","isPivotal":true,"enrollment":218,"indication":"Peripheral T-cell Lymphoma","completionDate":"2028-10-31"},{"nctId":"NCT01947140","phase":"Phase 1","title":"Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"Jennifer Amengual","isPivotal":false,"enrollment":57,"indication":"Lymphoid Malignancies, Multiple Myeloma","completionDate":"2022-09-01"},{"nctId":"NCT06561048","phase":"Phase 3","title":"A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participant","status":"RECRUITING","sponsor":"Corvus Pharmaceuticals, Inc.","isPivotal":true,"enrollment":150,"indication":"Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma","completionDate":"2028-07"},{"nctId":"NCT03240211","phase":"Phase 1","title":"Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabi","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Virginia","isPivotal":false,"enrollment":37,"indication":"PTCL, CTCL","completionDate":"2026-05-25"},{"nctId":"NCT01789723","phase":"Phase 1","title":"An Open Label, Multicenter, Dose Finding, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Receiving Folotyn® (P","status":"WITHDRAWN","sponsor":"Acrotech Biopharma Inc.","isPivotal":false,"enrollment":0,"indication":"Non Hodgkin's Lymphoma","completionDate":"2015-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}